Short answer
UroGen Pharma Ltd. (URGN) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). Filing signed March 2, 2026 by CFO Chris Degnan, confirming authorized execution of material agreement disclosure.
UroGen Pharma Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Filing signed March 2, 2026 by CFO Chris Degnan, confirming authorized execution of material agreement disclosure
- No deal terms, counterparty, or financial obligations disclosed in this section: full agreement details likely in attached exhibit
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 signals a new financial obligation (loan, credit facility, or guarantee) that increases UroGen's debt load or contingent liabilities
- No terms disclosed in provided text: full details likely in an accompanying exhibit or cross-referenced section
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UroGen Pharma Ltd. 8-K filings
Get the next URGN 8-K as it lands
Follow URGN for push alerts, or ask the research agent what this filing means.